Stock listing

ASX:1AD AdAlta Ltd. Share Price

Home listing (ASX) of AdAlta Ltd.

Follow AdAlta Ltd. into a list and get an email when it puts out news.

Share price · ASX:1AD

$0.0020 AUD -0.0010 (-33.3%)

Close on Nov 19, 2026

Past year -50.0% · daily closes, Nov 19, 2025 – Nov 19, 2026, adjusted for splits
Day range
$0.0020 – $0.0025 AUDNov 19, 2026
Volume
1.04M sharesNov 19, 2026
Market cap
$6.42M AUDAt the close on Nov 19, 2026 · price × 3.21B shares outstanding
52-week range
$0.0020 – $0.0080 AUDLowest and highest trades, Nov 20, 2025 – Nov 19, 2026
Traded on an average day
$6,593 AUDMedian day 434,250 shares · 14 days with no trades · last 3 months, Aug 19, 2026 – Nov 19, 2026
AdAlta Ltd. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
ASX:1AD · Home$0.0020 AUD-0.0010 (-33.3%)1,039,875$0.0025$0.0025$0.0020$0.0030Close on Nov 19, 2026

Daily closes

Last 3 months, Aug 19, 2026 – Nov 19, 2026 · ASX:1AD · AUD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$0.0020-0.0010-33.3%$0.0025$0.0025$0.00201,039,875
$0.00300.00000.0%$0.0030$0.0030$0.00300
$0.0030+0.0005+20.0%$0.0030$0.0030$0.00303,829,659
$0.00250.00000.0%$0.0025$0.0025$0.00250
$0.00250.00000.0%$0.0025$0.0025$0.00250
$0.0025+0.0005+25.0%$0.0030$0.0030$0.0025332,396
$0.0020-0.0005-20.0%$0.0020$0.0020$0.0020800,000
$0.00250.00000.0%$0.0025$0.0025$0.00250
$0.0025-0.0005-16.7%$0.0030$0.0030$0.00252,768,955
$0.0030+0.0010+50.0%$0.0030$0.0030$0.00202,260,222
$0.00200.00000.0%$0.0020$0.0020$0.00200
$0.00200.00000.0%$0.0020$0.0020$0.00204,500,000
$0.00200.00000.0%$0.0020$0.0020$0.00200
$0.00200.00000.0%$0.0030$0.0030$0.0020131,990
$0.0020-0.0010-33.3%$0.0030$0.0030$0.002038,151,684
$0.00300.00000.0%$0.0030$0.0030$0.00251,675,309
$0.0030-0.0005-14.3%$0.0035$0.0040$0.003045,016,546
$0.0035+0.0005+16.7%$0.0040$0.0040$0.0035324,080
$0.00300.00000.0%$0.0030$0.0030$0.00300
$0.00300.00000.0%$0.0030$0.0030$0.00300
$0.0030-0.0005-14.3%$0.0030$0.0030$0.0030410,647
$0.0035+0.0005+16.7%$0.0035$0.0035$0.003537,595
$0.00300.00000.0%$0.0030$0.0030$0.00300
$0.0030-0.0010-25.0%$0.0040$0.0040$0.0030887,750
$0.0040+0.0005+14.3%$0.0040$0.0040$0.0030928,764
$0.0035+0.0005+16.7%$0.0035$0.0035$0.00351,018,571
$0.0030-0.0005-14.3%$0.0035$0.0035$0.0030315,239
$0.00350.00000.0%$0.0035$0.0035$0.00350
$0.00350.00000.0%$0.0035$0.0035$0.0035200,000
$0.00350.00000.0%$0.0030$0.0035$0.003034,720
$0.00350.00000.0%$0.0030$0.0035$0.00301,919,234
$0.00350.00000.0%$0.0030$0.0035$0.0030282,311
$0.00350.00000.0%$0.0035$0.0035$0.0035147,312
$0.0035-0.0005-12.5%$0.0035$0.0040$0.0035505,000
$0.00400.00000.0%$0.0030$0.0040$0.0030564,463
$0.0040+0.0005+14.3%$0.0040$0.0040$0.00353,630,682
$0.0035+0.0005+16.7%$0.0035$0.0040$0.00353,525,466
$0.0030-0.0005-14.3%$0.0030$0.0030$0.0030103,333
$0.00350.00000.0%$0.0035$0.0035$0.0035596,875
$0.00350.00000.0%$0.0040$0.0040$0.003551,121
$0.0035-0.0005-12.5%$0.0040$0.0040$0.00351,200,000
$0.0040+0.0005+14.3%$0.0040$0.0040$0.0035534,177
$0.00350.00000.0%$0.0035$0.0035$0.00351,000,000
$0.00350.00000.0%$0.0040$0.0040$0.00351,130,001
$0.0035+0.0005+16.7%$0.0040$0.0040$0.003016,203,246
$0.00300.00000.0%$0.0030$0.0030$0.0030730,349
$0.00300.00000.0%$0.0030$0.0030$0.0030116,201
$0.00300.00000.0%$0.0030$0.0030$0.0030500,000
$0.00300.00000.0%$0.0030$0.0030$0.00300
$0.00300.00000.0%$0.0030$0.0030$0.00300
$0.00300.00000.0%$0.0030$0.0030$0.00300
$0.00300.00000.0%$0.0030$0.0030$0.00302,016,962
$0.00300.00000.0%$0.0030$0.0030$0.00300
$0.00300.00000.0%$0.0030$0.0035$0.00301,620,006
$0.0030-0.0010-25.0%$0.0040$0.0040$0.003030,908
$0.0040+0.0010+33.3%$0.0040$0.0040$0.00305,497,497
$0.00300.00000.0%$0.0040$0.0040$0.00302,043,275
$0.00300.00000.0%$0.0030$0.0030$0.0030166,667
$0.00300.00000.0%$0.0030$0.0030$0.00301,899,998
$0.00300.00000.0%$0.0030$0.0030$0.003074,000
$0.00300.00000.0%$0.0035$0.0035$0.003093,765
$0.0030-0.0005-14.3%$0.0030$0.0030$0.00301,498,964
$0.0035-0.0005-12.5%$0.0040$0.0040$0.0035198,514
$0.0040+0.0005+14.3%$0.0035$0.0040$0.0030434,250
$0.0035+0.0005+16.7%$0.0040$0.0040$0.0035471,243
$0.0030-0.0005-14.3%$0.0040$0.0040$0.0030486,802
$0.0035+0.0005+16.7%$0.0035$0.0035$0.003520,000

Splits

1 split · ASX:1AD · every price before a split is adjusted for it

DayRatioWhat
1-for-10Consolidation
Ticker
ASX:1AD
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
ASX
Currency
AUD

What changed lately

Latest news

EW-001 Orphan Drug Designation, pre-IND update

Nov 16, 2026

Closed $0.0030 (+20.0%) on Nov 17, 2026

$1.4m additional RDTI refund

Nov 11, 2026

Closed $0.0025 (+25.0%) on Nov 12, 2026

Change of AGM Date

Oct 27, 2026

Closed $0.0030 (-14.3%) on Oct 28, 2026

Quarterly Appendix 4C and Activities Report

Oct 25, 2026

Closed $0.0030 (0.0%) on Oct 26, 2026

RDTI receipt, Advanced Overseas Finding

Oct 18, 2026

Closed $0.0030 (-25.0%) on Oct 19, 2026

EW-001 JDC milestone approvals

Oct 4, 2026

Closed $0.0035 (-12.5%) on Oct 5, 2026

China Representative Office opens

Sep 30, 2026

Closed $0.0040 (+14.3%) on Oct 1, 2026

US FDA grants EW-001 pre-IND meeting

Sep 22, 2026

Closed $0.0040 (+14.3%) on Sep 23, 2026

All AdAlta Ltd. news

AdAlta Ltd. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
39 in the last 12 months · 188 in all · newest Nov 16, 2026 · oldest 2016
Decks
84 decks · latest Sep 10, 2026

Where AdAlta Ltd. is listed

ListingExchangeCountryCurrency
ASX:1AD · Home listing · This pageASXAustraliaAUD
Frankfurt:JDAFrankfurtGermanyEUR

Valuation

Price/book 17.4× against a median of 0.8×: the highest of 9 Biotechnology companies shown. Statements: Year to Jun 30, 2026 · price Nov 19, 2026

Enterprise value
$5.14M AUD
P/E
Loss
EV/sales
No revenue
EV/EBITDA
No depreciation figure on 6ix yet
Price/book
17.4×
Gross margin
No revenue
Operating margin
No revenue
Net margin
No revenue
Debt to equity
0.0×
Beta
No index for this market yet

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
AdAlta Ltd. · ASX:1ADUS$4.25MUS$3.40Mn/an/an/a17.4×n/a0.0×n/a
NFL Biosciences SA · EURONEXT:ALNFLUS$4.71MUS$5.36Mn/an/an/an/an/an/an/a
TheraCryf PLC · LSE:TCFUS$4.64MUS$2.63Mn/an/an/a1.3×n/a0.0×n/a
Pulmatrix, Inc. · NASDAQ:PULMUS$4.64MUS$3.24Mn/an/an/a3.5×n/a0.0×0.33
AIM ImmunoTech Inc. · AMEX:AIMUS$4.57M−US$937,186n/a−10.3×n/a0.7×n/a0.2×0.66
Tissue Repair Ltd · ASX:TRPUS$4.40MUS$1.24Mn/a3.4×n/a0.8×−958.0%0.0×n/a
Processa Pharmaceuticals, Inc. · NASDAQ:PCSAUS$4.37M−US$175.8Mn/an/an/an/an/an/a1.60
Percheron Therapeutics Limited · ASX:PERUS$3.94MUS$1.27Mn/an/an/a0.8×n/a0.0×n/a
Lantern Pharma Inc. · NASDAQ:LTRNUS$3.89M−US$3.69Mn/an/an/a2.8×n/a0.0×2.80
Silo Pharma, Inc. · NASDAQ:SILOUS$3.77M−US$4.28Mn/an/an/a0.5×n/a0.0×1.23
Alzamend Neuro, Inc. · NASDAQ:ALZNUS$3.74M−US$3.85Mn/an/an/a0.7×n/a0.0×2.00
Median of the othersUS$4.38MUS$153,720−3.5×0.8×−958.0%0.0×1.42

Team and board

Officers

OfficerRole
Tim OldhamCEO & MANAGING DIRECTOR
Cameron JonesCOMPANY SECRETARY
Janette Dixon DBAHead of Business Development
Kevin Lynch MBBSConsultant Chief Medical Officer – Oncology

Board

DirectorRole
Paul MacLemanCHAIRMAN
Fadi DiabNON-EXECUTIVE DIRECTOR
Michelle BurkeNON-EXECUTIVE DIRECTOR

Events

QuarterResultsShare move
Q4 2025Aug 26, 20250.0%
Q2 2025Feb 20, 20250.0%
Q2 2023Feb 27, 2023 · After close0.0%
Q4 2022Aug 28, 2022 · After close0.0%
Q2 2022Feb 22, 2022 · After close+1.6%
Q4 2021Aug 26, 2021 · After close−3.7%
Q2 2021Feb 25, 2021 · Before open−5.7%

Open Events

Decks

DeckKindSlidesDate
BIOSeedin Autumn Innovation Partnering Summit 2026Conference35 slidesSep 10, 2026
Investor Presentation (August 2026)Investor deck35 slidesAug 13, 2026
ISCT ANZ 2026 Regional MeetingConference14 slidesJul 20, 2026
Investor Presentation (April 2026)Investor deck16 slidesMay 11, 2026
ANZ Biologics Festival 2026Conference21 slidesFeb 4, 2026
Investor Presentation (January 2026)Investor deck17 slidesJan 15, 2026
Shareholder Meeting (November 2025)Shareholder meeting25 slidesNov 26, 2025
Investor Presentation (August 2025)Investor deck27 slidesAug 19, 2025
Investor Presentation (July 2025)Investor deck27 slidesJul 30, 2025
Investor Presentation (May 2025)Investor deck28 slidesMay 7, 2025
Show 50 decks
DeckKindSlidesDate
4th BioCentury-BayHelix East-West Biopharma Summit 2025Conference18 slidesMar 4, 2025
Investor Presentation (February 2025)Investor deck16 slidesFeb 11, 2025
Investor Presentation (February 2025)Investor deck24 slidesFeb 7, 2025
Biotech Showcase 2025Conference25 slidesJan 10, 2025
2024 ASCEPT, APFP & APSA Joint CongressConference27 slidesDec 2, 2024
Investor Presentation (November 2024)Investor deck49 slidesNov 21, 2024
Shareholder Meeting (November 2024)Shareholder meeting31 slidesNov 20, 2024
Investor Presentation (August 2024)Investor deck47 slidesAug 21, 2024
Investor Presentation (May 2024)Investor deck47 slidesMay 20, 2024
Investor Presentation (May 2024)Investor deck10 slidesMay 1, 2024
Corporate Update (April 2024)Corporate update18 slidesApr 10, 2024
Investor Presentation (March 2024)Investor deck30 slidesMar 8, 2024
Australia Biologics Festival 2024Conference27 slidesFeb 20, 2024
Advanced Therapies Week 2024Conference20 slidesJan 22, 2024
Shareholder Meeting (November 2023)Shareholder meeting31 slidesNov 22, 2023
Investor Presentation (October 2023)Investor deck39 slidesOct 27, 2023
Discovery on Target 2023Conference32 slidesSep 26, 2023
Investor Presentation (July 2023)Investor deck31 slidesJul 13, 2023
Investor Presentation (May 2023)Investor deck27 slidesMay 25, 2023
Investor Presentation (May 2023)Investor deck29 slidesMay 3, 2023
ShareCafe Small Cap Hidden Gems Webinar (March 2023)Conference21 slidesMar 2, 2023
Spark Plus Singapore Biotech Day 2023Conference28 slidesFeb 24, 2023
Shareholder Meeting (November 2022)Shareholder meeting35 slidesNov 22, 2022
Corporate Update (November 2022)Corporate update22 slidesNov 2, 2022
Investor Presentation (July 2022)Investor deck23 slidesJul 25, 2022
BIO International Convention 2022Conference25 slidesJun 1, 2022
16th Bioshares Biotech Summit 2022Conference20 slidesMay 10, 2022
Inaugural PAC Partners Healthcare Conference 2022Conference67 slidesApr 5, 2022
ShareCafe Small Cap "Hidden Gems" Webinar (January 2022)Conference16 slidesJan 20, 2022
Biotech Showcase 2022 Virtual conferenceConference26 slidesJan 4, 2022
Investor Presentation (December 2021)Investor deck68 slidesDec 15, 2021
Shareholder Meeting (November 2021)Shareholder meeting25 slidesNov 29, 2021
AusBiotech Invest 2021 and BIO-Europe Digital 2021Conference28 slidesOct 22, 2021
IRD Invest 2021Conference62 slidesSep 21, 2021
Corporate Update (August 2021)Corporate update18 slidesAug 25, 2021
Corporate Update (July 2021)Corporate update28 slidesJul 19, 2021
Investor Presentation (June 2021)Investor deck44 slidesJun 3, 2021
ILD Drug Development Summit 2021Conference26 slidesApr 28, 2021
Corporate Update (March 2021)Corporate update35 slidesMar 10, 2021
Shareholder Meeting (November 2020)Shareholder meeting28 slidesNov 25, 2020

This page holds 50 of 84 decks. Open Decks

Open Decks

Financings

RaiseDateIn US dollars
Private placement of fully paid ordinary shares with attaching options
Announced: A$2.5M · A$0.004 a share · Warrants at A$0.01 · 62 Capital Pty Ltd
Dealers: 62 Capital Pty Ltd (lead)
Use of proceeds: Advance BZDS1901 CAR-T therapy: obtain US FDA pre-IND guidance and establish Australian manufacturing; execute East to West strategy
May 4, 2026US$1.79M
Private placement of fully paid ordinary shares with attaching ASX:1ADO options
Update: A$1.2M · A$0.005 a share · 62 Capital Pty Ltd
Dealers: 62 Capital Pty Ltd (lead)
Use of proceeds: Advance AdCella's East to West cell therapy strategy, other transactions, i-body intellectual property and general working capital
Jan 30, 2026US$838,637

Open Financings · Read by 6ix AI from the company's releases

Financials

Annual, in AUD

Income statement

LineFY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Revenue677.0K1.74M3.47M2.76M3.99M3.85M3.54M2.02M1.80M
Cost of revenue219.5K229.9K29.9K260.6K7.01M7.01M32.5K3.14K5.43K
Gross profit457.5K1.51M3.44M987.9K848.2K-6.40M3.51M2.02M1.79M
Research and development3.34M2.20M4.16M3.65M4.13M6.23M6.23M
Selling, general and administrative1.19M2.56M2.40M4.19M4.33M2.94M1.41M245.0K833.9K207.0K
Operating income-4.80M-4.38M-5.26M-8.34M-7.76M-8.55M-9.05M-9.53M-5.88M-4.80M
Depreciation and amortization85.2K63.0K29.9K33.1K29.1K41.8K32.5K3.14K5.43K
EBITDA-4.29M-5.20M-8.31M-7.73M-8.53M-9.01M-9.50M-5.88M-4.79M
Interest expense290.9K62.3K115.0K123.8K111.4K97.6K115.5K115.5K59.8K0
Income before tax-5.09M-4.50M-7.12M-7.73M-6.06M-5.63M-6.01M-9.42M-5.88M-4.61M
Income tax-404.2K-677.0K-1.74M-2.88M111.4K97.6K115.5K-3.50M-2.02M-1.78M
Net income-4.68M-4.50M-5.38M-4.85M-6.06M-5.63M-6.01M-5.92M-3.85M-2.83M
Earnings per share, basic-0.00-0.03-0.05-0.08-0.02-0.12-0.18-0.28-0.18-0.15

Balance sheet

LineFY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Cash and equivalents1.28M1.31M3.34M4.79M8.66M5.79M3.37M5.56M2.31M6.22M
Short-term investments-206.3K04.01M
Receivables273.6K836.0K1.82M2.49M40.0K2.98M3.31M3.58M2.08M1.84M
Inventory-1.95M-2.49M1-2.98M-3.31M-3.58M-2.08M-1.84M
Current assets1.72M2.14M5.29M7.70M10.6M8.98M6.73M9.17M4.44M8.09M
Property, plant and equipment0282.1K36.0K63.8K71.7K98.6K138.1K00
Total assets1.72M2.14M5.57M7.73M10.6M9.05M6.91M9.31M4.44M8.09M
Accounts payable312.1K641.8K92.9K1.12M555.5K215.7K540.8K1.51M74.6K10.4K
Current liabilities1.35M1.34M2.22M5.81M3.63M2.66M3.21M1.82M366.3K344.5K
Long-term debt1.32M1.09M01.61M
Total debt1.77M2.70M4.01M4.00M1.69M2.19M2.19M
Total liabilities1.35M2.74M3.54M5.82M5.27M2.66M3.21M1.82M366.3K344.5K
Shareholders' equity370.2K-598.2K2.03M1.91M5.38M6.39M3.70M7.49M4.07M7.75M
Shares outstanding2.05B130.6M98.9M63.7M278.4M47.3M33.7M20.8M21.6M19.2M

Cash flow

LineFY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Cash from operations-4.44M-2.94M-5.26M-5.13M-4.09M-4.78M-5.89M-5.82M-3.93M-3.73M
Capital spending0-3-62.4K-2.13K-25.2K-2.12K-2.38K-170.6K-3.14K-6.75K
Free cash flow-4.44M-2.94M-5.32M-5.13M-4.11M-4.78M-5.89M-5.99M-3.93M-3.73M
Cash from investing109.6K-62.4K-2.13K-25.2K-2.12K-2.38K-170.6K-3.14K-8.35K
Cash from financing4.42M999.1K3.67M1.27M7.02M7.19M3.70M9.24M13.2K9.47M
Dividends paid-2.76M-5.18M-3.55M
Share buybacks-81.9K-185.7K-286.1K-70.9K-266.0K-327.5K-153.2K-716.1K13.2K-584.8K
Change in cash-21.3K-1.83M-1.66M-3.87M2.87M2.42M-2.19M3.25M-3.92M5.74M

Open Financials

Filings

FilingDateTypeFiled with
EW-001 Orphan Drug Designation, pre-IND updateNov 16, 2026Operations updateASX
$1.4m additional RDTI refundNov 11, 2026ResultsASX
Letter to Shareholders, Notice of AGM & Proxy FormOct 29, 2026Meeting noticeASX
Change of AGM DateOct 27, 2026Meeting noticeASX
Quarterly Appendix 4C and Activities ReportOct 25, 2026Quarterly reportASX
RDTI receipt, Advanced Overseas FindingOct 18, 2026ResultsASX
RDTI receipt, Advanced Overseas FindingOct 18, 2026ResultsASX
EW-001 JDC milestone approvalsOct 4, 2026Other filingsASX
China Representative Office opensSep 30, 2026Operations updateASX
Date of AGM & Closing Date for Director NominationsSep 29, 2026Meeting noticeASX
All 178 filings
FilingDateTypeFiled with
US FDA grants EW-001 pre-IND meetingSep 22, 2026Operations updateASX
Oribiotech deal validates AdAlta manufacturing strategySep 17, 2026Operations updateASX
CAR-TCR Summit posterSep 14, 2026Operations updateASX
Bilingual BIOSeedin Investor PresentationSep 9, 2026Operations updateASX
BZDS1901 special access scheme launch in ChinaSep 1, 2026Operations updateASX
Appendix 4G and Corporate Governance StatementAug 21, 2026Other filingsASX
Annual Report to shareholdersAug 21, 2026Annual reportASX
Preliminary Final ReportAug 21, 2026ResultsASX
Investor presentationAug 12, 2026Other filingsASX
EW-001 IIT study overall survival updateAug 9, 2026Other filingsASX
2 year survival milestone for EW-001 patientAug 4, 2026Other filingsASX
Quarterly Appendix 4C and Activities ReportJul 28, 2026Quarterly reportASX
Oktopi AI collaboration for research efficiencyJul 1, 2026Operations updateASX
Second BZDS1901 milestone paidJun 30, 2026Other filingsASX
Regulatory advisors appointed for BZDS1901May 24, 2026Operations updateASX
$2.5m placementMay 4, 2026FinancingASX
BZDS1901 manufacturing agreementApr 28, 2026Other filingsASX
Automated cell therapy manufacturing MoUApr 20, 2026Operations updateASX
BZDS1901 clinical updateMar 31, 2026Other filingsASX
AdCella and SHcell hold first JDC meetingMar 26, 2026Operations updateASX
New AD-214 patent grantedMar 19, 2026Other filingsASX
AdCella expands clinical advisory boardMar 3, 2026Other filingsASX
AdCella Clinical Advisory Board convenedFeb 25, 2026Other filingsASX
Half Yearly Report and AccountsFeb 19, 2026Interim reportASX
Quarterly Appendix 4C and Activities ReportJan 29, 2026Quarterly reportASX
AdCella milestones and regulatory progressJan 20, 2026Operations updateASX
Placement raises A$1.2 millionJan 12, 2026FinancingASX
CAR-T collaboration agreementJan 1, 2026Operations updateASX
$0.78 million FY25 RDTI refund receivedDec 3, 2025ResultsASX
AGM share consolidation resolution withdrawalNov 6, 2025Meeting outcomeASX
Meurs Group Investment Agreement UpdateOct 27, 2025FinancingASX
NLSC investment balance repaidOct 23, 2025FinancingASX
Letter to Shareholders, Notice of AGM & Proxy FormOct 23, 2025Meeting noticeASX
At market Placement raises additional up to A$1.1 millionOct 19, 2025FinancingASX
Placement raises up to A$0.5 million and transaction updateOct 12, 2025FinancingASX
Preliminary Final ReportAug 26, 2025ResultsASX
Investor Presentation - TechKnow Invest RoadshowAug 18, 2025Other filingsASX
Renounceable Rights Issue shortfall placedJun 12, 2025FinancingASX
Rights Issue raises $1.1millionJun 2, 2025FinancingASX
Notice of change of exercise price of optionsMay 28, 2025Other filingsASX
ProspectusMay 4, 2025Offer documentASX
Renounceable Rights Issue to Raise up to $1.3 millionMay 1, 2025FinancingASX
Trading HaltApr 29, 2025Trading halt or suspensionASX
SYNBV invest up to $2m in East to West subsidiaryMar 19, 2025FinancingASX
R&D Tax Incentive advance receivedMar 4, 2025Other filingsASX
Investor PresentationFeb 6, 2025Other filingsASX
East to West cell therapy strategy updateFeb 5, 2025Operations updateASX
AD-214 clinical advisory boardOct 9, 2024Other filingsASX
FY24 RDTI Refund Received $1.77mOct 3, 2024ResultsASX
Transaction, investment facility updateSep 2, 2024FinancingASX
$1.9 million raised from exercise of 1ADOA optionsJun 2, 2024FinancingASX
Cellular immunotherapy manufacturer secured - Cell TherapiesMay 12, 2024Operations updateASX
Extension of Victorian Government RDTI Loan FacilityApr 28, 2024FinancingASX
Institutional investment to pursue strategic initiativesApr 28, 2024FinancingASX
SYNBV MoU Webinar presentationApr 9, 2024Other filingsASX
SYNThesis BioVentures MoU for cellular immunotherapiesApr 7, 2024Operations updateASX
Corporate PresentationMar 7, 2024Other filingsASX
Positive AD-214 Phase I extension study resultsMar 5, 2024Other filingsASX
January 2024 partnering presentations and progressJan 21, 2024Other filingsASX
New malaria inhibiting i-bodyDec 18, 2023Other filingsASX
Chair address and CEO presentation to AGMNov 21, 2023Annual reportASX
AD-214 Phase I extension clinical study - interim resultsNov 20, 2023ResultsASX
Oversubscribed placement resultNov 6, 2023FinancingASX
Placement to raise up to $1.23millionNov 2, 2023FinancingASX
AD-214 well tolerated in Phase I extension studyOct 22, 2023Operations updateASX
R&D tax refund received & R&D Loan repayment terms extendedOct 17, 2023FinancingASX
Prof Foley invited presentation AD-214Sep 25, 2023Other filingsASX
Dosing simulations support AD-214 IV product profileSep 24, 2023Other filingsASX
AD-214 Phase I extension study fully enrolledSep 19, 2023Other filingsASX
AD-214 returns to clinicAug 3, 2023Other filingsASX
$1.87 million raised in oversubscribed Shortfall facilityJul 12, 2023Other filingsASX
New AD-214 data de-risks clinical studiesJul 6, 2023Other filingsASX
AD-214 clinical trial approvalJun 28, 2023Other filingsASX
Rights Offer resultsMay 24, 2023Other filingsASX
Rights Offer to fund early return to clinic and growthApr 27, 2023Other filingsASX
Publication highlights I-body potential in osteoporosisJan 24, 2023Other filingsASX
AdAlta welcomes new substantial shareholdersJan 23, 2023Other filingsASX
Second Japan patent for AD-214Jan 9, 2023Other filingsASX
AD-214 progress and priorities webinar presentationNov 1, 2022Other filingsASX
AD-214 progress and prioritiesNov 1, 2022Other filingsASX
Balance of R&D Tax Incentive Refund receivedOct 26, 2022Other filingsASX
1AD & GPCR Therapeutics to evaluate CXCR4 i-bodies in cancerOct 12, 2022Other filingsASX
R&D Tax Incentive Refund receivedOct 3, 2022Other filingsASX
AD-214 program update, cash runway extensionJul 3, 2022Other filingsASX
European Patent for AD-214 grantedJun 13, 2022Other filingsASX
BIO International Convention presentationMay 31, 2022Other filingsASX
AdAlta presentation at Bioshares Biotech SummitMay 9, 2022Other filingsASX
Indian patent for AD-214Apr 6, 2022Other filingsASX
Inhaled AD-214 preclinical programApr 4, 2022Other filingsASX
PAC Partners Healthcare Conference - Corporate PresentationApr 4, 2022Other filingsASX
$1.6M Second Tranche R&D Cash Flow Loan ReceivedMar 8, 2022Other filingsASX
Chinese patent granted for AD-214Mar 1, 2022Other filingsASX
Entitlement Offer ResultsFeb 3, 2022FinancingASX
Entitlement Offer BookletDec 22, 2021FinancingASX
Reinstatement to QuotationDec 14, 2021Trading halt or suspensionASX
Voluntary SuspensionDec 13, 2021Trading halt or suspensionASX
Inhaled AD-214 passes first development milestoneDec 8, 2021Other filingsASX
AGM presentations & first iCAR-T dataNov 28, 2021Other filingsASX
Second US patent for AD-214Nov 17, 2021Other filingsASX
BTB funding transferred to AD-214 inhalation programOct 6, 2021Other filingsASX
New pre-clinical data presented at Boston conferenceSep 26, 2021Other filingsASX
Corporate overview and IRD Invest 2021 presentationSep 20, 2021Other filingsASX
$4.0M Non-Dilutive Financing with Victorian GovernmentSep 19, 2021Other filingsASX
Carina collaboration webinar presentationAug 25, 2021Other filingsASX
CAR-T collaboration with Carina BiotechAug 23, 2021Other filingsASX
Webinar and presentation on AD-214 strategyJul 19, 2021Other filingsASX
AD-214 pathway to IPF efficacy studiesJul 18, 2021Other filingsASX
AdAlta secures AD-214 resupplyJul 1, 2021Other filingsASX
R&D Tax Incentive FacilityJun 24, 2021Other filingsASX
GE Healthcare collaboration advances to next stageMay 23, 2021Other filingsASX
AdAlta granted Japanese patent for AD-214May 18, 2021Other filingsASX
Mutiple Dose Part Of Ad-214 Phase I Trial CommencedApr 18, 2021Other filingsASX
Investor briefing-AD-214 top line single dose safety resultsMar 9, 2021Other filingsASX
Appendix 4D and Interim Financial ReportFeb 25, 2021Interim reportASX
FDA Orphan Drug Designation for AD-214Feb 23, 2021Other filingsASX
Phase I HV extension to explore encouraging resultsDec 13, 2020Other filingsASX
AGM PresentationNov 25, 2020Other filingsASX
AusBiotech presentation including Phase I status updateOct 26, 2020Other filingsASX
Investor Presentation - BIO investor forumOct 9, 2020Other filingsASX
GE Healthcare collaboration progressesSep 20, 2020Other filingsASX
Non-renounceable Rights Issue OfferAug 18, 2020FinancingASX
Placement and Rights OfferAug 10, 2020FinancingASX
Investor presentation including future milestonesJul 29, 2020Other filingsASX
First participants treated in AD-214 Phase I trialJul 23, 2020Other filingsASX
Supportive US FDA pre-IND meeting results for AD-214Jul 19, 2020Other filingsASX
AdAlta receives approval to commence AD-214 Phase I trialJun 9, 2020Other filingsASX
Business update and COVID-19 responseMar 30, 2020Operations updateASX
Board changes and R&D Tax Incentive advance receivedMar 26, 2020Other filingsASX
Investor Briefing - Strategic PlanMar 2, 2020Other filingsASX
AD-214 effective in gold standard pre-clinical animal modelMar 1, 2020Other filingsASX
Appendix 4C - quarterlyJan 30, 2020Quarterly reportASX
AdAlta Granted US Patent for AD-214Jan 29, 2020Other filingsASX
AD-214 Phase I strategy and timing updateJan 13, 2020Other filingsASX
AdAlta awarded Biomedical Translation Bridge FundingDec 12, 2019Other filingsASX
GLP Toxicology study resultsOct 28, 2019Other filingsASX
Tim Oldham Appointed as Chief Executive OfficerOct 8, 2019Other filingsASX
Receipt of R&D Tax IncentiveSep 17, 2019Other filingsASX
AdAlta secures licensing deal with GE HealthcareSep 15, 2019Other filingsASX
Executive team changesAug 11, 2019Other filingsASX
GLP toxicology study commencesJul 15, 2019Other filingsASX
Entitlement Offer Results and Shortfall NotificationJun 14, 2019FinancingASX
Completion of Capital Raise - $5 millionMay 23, 2019Other filingsASX
AD-214 manufacturing updateMay 2, 2019Other filingsASX
Manufacturing updateJan 28, 2019Other filingsASX
Appendix 4C - Quarter ended 30 September 2018Oct 16, 2018Quarterly reportASX
Manufacturing UpdateOct 14, 2018Other filingsASX
Change of Registry Address: Automic P/L - Sydney OfficeSep 28, 2018Other filingsASX
Investor presentation and conference callJul 31, 2018Other filingsASX
Appendix 4C - Quarter ended 30 June 2018Jul 15, 2018Quarterly reportASX
Completion of Capital Raise - $4.25m to advance AD-214Jul 12, 2018Other filingsASX
AdAlta secures key manufacturing agreements for AD-214Jun 4, 2018Other filingsASX
Appendix 4C - Quarter Ended 31 March 2018Apr 22, 2018Quarterly reportASX
AdAlta to advance improved lung fibrosis therapy, AD-214Apr 17, 2018Other filingsASX
AdAlta collaborator awarded NHMRC grantDec 6, 2017Other filingsASX
AdAlta granted key Australian PatentNov 16, 2017Other filingsASX
Commercial agreement with XL-proteinNov 13, 2017Other filingsASX
Conference PresentationOct 31, 2017Other filingsASX
Results of multi-dose toxicology studySep 18, 2017Other filingsASX
AdAlta awarded SIEF grantJul 23, 2017Other filingsASX
Toxicology study and manufacturing updateJul 17, 2017Other filingsASX
Presentation of Eye Fobrosis Data at ARVO MeetingMay 8, 2017Other filingsASX
AdAlta expands partnership with Alfred HospitalMar 20, 2017Other filingsASX
AdAlta receives Orphan Designation for AD-114Jan 18, 2017Other filingsASX
Positive Pre-clinical DataJan 8, 2017Other filingsASX
Commercialisation Agreement with Crossbeta BiosciencesNov 7, 2016Other filingsASX
Quarterly Review and Appendix 4COct 26, 2016Quarterly reportASX
Receipt of Innovation Connections GrantSep 13, 2016Other filingsASX
Agreement with FujiFilm Diosynth BiotechnologiesSep 12, 2016Other filingsASX

Open Filings

Cap table

Built by 6ix from AdAlta Ltd.’s releases · as of May 4, 2026

Common shares
3,212,169,031
Fully diluted
3,212,169,031

Fully diluted

LineShares
Common shares3,212,169,031

Share count over time

CountShares
Nov 22, 20263,212,169,031

Open Cap table

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Cameron JonesCOMPANY SECRETARY · Since at least Nov 5, 2026
Fadi DiabNON-EXECUTIVE DIRECTOR · Since at least Nov 5, 2026
Janette Dixon DBAHead of Business Development · Since at least Nov 4, 2026
Kevin Lynch MBBSConsultant Chief Medical Officer – Oncology · Since at least Nov 4, 2026
Michelle BurkeNON-EXECUTIVE DIRECTOR · Since at least Nov 5, 2026
Paul MacLemanCHAIRMAN · Since at least Nov 5, 2026
Tim OldhamCEO & MANAGING DIRECTOR · Since at least Nov 4, 2026

Open People

Log in to ask 6ix AI your own questions about AdAlta Ltd.